Skip links

info@visionofresearch.ae

14th Floor, Dubai Science Park South Tower - Al Barsha South - Dubai - UAE

+971-561224424

Start a Project

Academic & Research Platforms

University & Discovery-Oriented Services

Preclinical Drug Evaluation Platforms

Regulatory & Decision-Ready Services

1.End-to-End Research Project Design

2.Scientific Positioning & Topic Strategy

3.Hypothesis & Research Question Engineering

4.Study Methodology & Experimental Workflow

5.Statistical Design & Power Analysis

6.Biomarker, Gene & Target Strategy

7.Assay Selection & Validation Planning

8.Translational & Regulatory Alignment

9.Risk Management, Quality & Reproducibility

10.Data Analysis, Reporting & Scientific Support

1.Neurology & Neuroscience

2.Metabolic & Endocrine Models

3.Cardiovascular & Stroke Models

4.Reproductive & Fertility Models

5.Immunology & Inflammation

6.Liver & Kidney Disease Models

7.Gastrointestinal & Microbiome

8.Regenerative & Wound Healing

9.Toxicology & Safety Models

10.Ocular & Retinal Disease Models

11.Respiratory Disease Models

12.Musculoskeletal & Arthritis Models

13.Urology & Renal Function Models

14.Ocular & Retinal Disease Models

1.Learning, Memory & Cognition

2.Anxiety & Stress Behavior Assessment

3.Depression & Motivation Behavior

4.Pain & Nociception Assessment

5.Motor Function & Coordination

6.Sensorimotor Integration & Reflexes

7.Seizure & Epilepsy-Related Behavior

8.Sleep & Circadian Rhythm

9.Social Behavior & Communication

10.Reward, Addiction & Motivation

11.Fatigue & Exercise Capacity

12.Gastrointestinal & Feeding Behavior

13.Metabolic & Energy Balance

14.Urinary & Bladder Function

15.Cardiovascular Function & Stroke

16.Regenerative Functional Readouts

17.General Activity, Locomotion

Clinical Monitoring

  • General Appearance & Condition
  • Behavior & Stress Indicators
  • Grooming & Coat Condition
  • Respiratory Patterns & Function
  • Toxicity & Distress Signs
  • Body Weight & Growth Monitoring
  • Food Intake & Nutritional Status
  • Hydration & Fluid Balance

Hematological & Biochemical

  • Complete Blood Count (CBC)
  • Clinical Biochemistry Panels
  • Electrolyte

1.Gene Expression (PCR-based)

2.Nucleic Acid Extraction & Synthesis

3.Design of Nucleotide Primer Sequences

4.PCR & Advanced Molecular Analysis 

5.DNA & RNA Quantification

6.Agarose Gel Electrophoresis Performance

7.Epigenetic and DNA Methylation Assays

8.Transcriptomic and RNA-Seq Analysis

9.CRISPR-Based Genetic Validation Assays

10.Protein Expression (WB)

11.Biomarker Quantification (ELISA)

1.Cell Line Preparation & Treatment

2.Cell Viability, Proliferation & Cytotoxicity

3.Cell Migration, Invasion & Angiogenesis

4.Flow Cytometry & Cell Fate Analysis

5.Oxidative Stress & Drug Response

6.Cell Labeling, Tracking & Differentiation

7.Imaging & Microscopy

8.Organ-on-a-Chip & Advanced In-Vitro Models

9.Advanced Cellular & Molecular Platforms

10.Protein, Antibody & Omics-Related Services

1.IHC, IF & TUNEL assay

2.Fluorescent Staining Techniques

3.Specialized Staining Techniques

  • Structural and Morphological Tissue
  • Fibrosis and Extracellular Matrix
  • Neurodegeneration & Neural Integrity
  • Metabolic Changes & Lipid Accumulation
  • Mineralization and Calcification
  • Vascular Structure and Elastic Fibers
  • Inflammation & Immune Response
  • Vital Function & Cellular Differentiation
  • Microbiological Staining Techniques
  • Microscopic Imaging Platforms

1.Quantitative Analysis & Reporting

2.Tissue Evaluation & Analysis

3.Qualitative & Semi-Quantitative Analysis

4.Scientific & Regulatory Support

1.Isolation, Culture & Identification

2.Biochemical & Phenotypic Characterization

3.Antimicrobial & Antibiotic Evaluation

4.Mechanism of Action & Antimicrobial Resistance

5.Applied & Industrial Microbiology Services

1.Plant Extraction

2.Plant Extract Drying

3.Essential Oil Synthesis

4.Nanoparticle Synthesis

5.Exosome Isolation

  • Neurology & Neuroscience
  • Metabolic & Endocrine Models
  • Cardiovascular & Stroke Models
  • Reproductive & Fertility Models
  • Immunology & Inflammation
  • Liver & Kidney Disease Models
  • Gastrointestinal & Microbiome
  • Regenerative & Wound Healing
  • Toxicology & Safety Models
  • Ocular & Retinal Disease Models
  • Respiratory Disease Models
  • Musculoskeletal & Arthritis Models
  • Urology & Renal Function Models
  • Ocular & Retinal Disease Models
  • Learning, Memory & Cognition
  • Anxiety & Stress Behavior Assessment
  • Depression & Motivation Behavior
  • Pain & Nociception Assessment
  • Motor Function & Coordination
  • Sensorimotor Integration & Reflexes
  • Seizure & Epilepsy-Related Behavior
  • Sleep & Circadian Rhythm
  • Social Behavior & Communication
  • Reward, Addiction & Motivation
  • Fatigue & Exercise Capacity
  • Gastrointestinal & Feeding Behavior
  • Metabolic & Energy Balance
  • Urinary & Bladder Function
  • Cardiovascular Function & Stroke
  • Regenerative Functional Readouts
  • General Activity, Locomotion

Daily Clinical Monitoring

  •  General Appearance & Condition
  • Behavior & Stress Indicators
  • Grooming & Coat Condition
  • Respiratory Patterns & Function
  • Toxicity & Distress Signs
  • Body Weight & Growth Monitoring
  • Food Intake & Nutritional Status
  • Hydration & Fluid Balance

 

Hematological & Biochemical

  • Complete Blood Count (CBC)
  • Clinical Biochemistry Panels
  • Electrolyte & Mineral Balance
  • Tissue Sample Preparation & Processing
    • Imaging Systems & Analysis Platforms
    • IHC, IF & TUNEL assay
    • Fluorescent Staining Techniques
    • Specialized Staining Techniques
    • Structural and Morphological Tissue
    • Fibrosis and Extracellular Matrix
    • Neurodegeneration & Neural Integrity
    • Metabolic Changes & Lipid Accumulation
    • Mineralization and Calcification
    • Vascular Structure and Elastic Fibers
    • Inflammation & Immune Response
    • Vital Function & Cellular Differentiation
    • Microbiological Staining Techniques
    • Microscopic Imaging Platforms
  • Qualitative & Semi-Quantitative Analysis
  • Scientific & Regulatory Support
  • Quantitative Analysis & Reporting
  • Discovery & Target Identification
  • In Vivo Functional Characterization
  • Exposure–Response Confirmation
  • Mechanistic Validation & Pathway Mapping
  • Strategic Biomarker Prioritization
  • Cell Viability & Cytotoxicity Screening
  • Mechanistic & Molecular Pathway Assays
  • Target Engagement & Binding Studies
  • Functional Potency & Cellular Response
  • In Vitro ADME & Metabolic Stability
  • Advanced 3D & Complex Cellular Models
  • Immunogenicity & Immunotoxicity Assessment
  • Biophysical & Chemical Stability Profiling
  • Preclinical-to-Clinical Biomarker Strategy
  • Translational Correlation (In Vivo ↔ Clinical)
  • Clinical Assay Development & Optimization
  • Biomarker Strategy for Clinical Development
  • Regulatory-Ready Biomarker Documentation
  • PK/PD & Clinical Pharmacology
  • Core PK/TK Assessment Framework
  • PK Sampling Timepoint Design & Optimization
  • Bioanalytical Platforms & Methods

                  (Modality-Specific Detection Platforms)

  • Primary PK Objectives
  • PK–PD Modeling & Simulation

                  (The Quantitative Engine for Rational Dosing)

  • Biodistribution & Tissue Mapping Studies
  • Specialized In Vitro ADME Analysis
  • In Vivo Pharmacokinetic Studies
  • Macromolecule (Biologics) Bioanalysis
  • Small-Molecule Drug Bioanalysis
  • Custom Drug Quantification Method Development
  • Target Engagement & Pathway Modulation Assays
  • Physicochemical Stability & Degradation Profiling
  • Functional Potency & Biological Activity Assessment
  • Receptor Binding Kinetics & Affinity Measurement
  • Inflammatory Pathway Assessment
  • Oxidative Stress & Antioxidant Profiling
  • Metabolic Function & Hormonal Analysis
  • Fibrosis & Extracellular Matrix Evaluation
  • Apoptosis & Cellular Proliferation Monitoring
  • Vascular Function & Angiogenesis Studies
  • Immune Response & Activation Profiling
  • FDA, U.S. Food & Drug Administration
  • EMA, European Medicines Agency
  • GCC Regulatory Authorities (GCC-DR, Saudi/GCC Union)
  • SFDA, Saudi Food & Drug Authority
  • MOHAP, Ministry of Health & Prevention (UAE)
Visionofresearch

Daily Clinical & Biochemical Monitoring

 Daily clinical and behavioral monitoring, combined with systematic hematological and biochemical assessment, is fundamental to scientific accuracy, safety, and ethical compliance in animal studies. This integrated approach enables structured evaluation of general condition, behavior, stress indicators, respiration, food intake, and body weight, alongside quantitative laboratory analyses including CBC, liver and kidney function, metabolic, lipid, and electrolyte profiles.

Protocol-defined monitoring at baseline, interim, and terminal timepoints allows early detection of toxicity, physiological shifts, or abnormal disease progression, ensuring animal welfare and reliable data interpretation. Baseline clinical and hematological profiling establishes individual reference values prior to intervention, enabling accurate differentiation between true treatment effects and normal biological variability while providing regulatory-ready safety documentation aligned with FDA and EMA standards.

This framework translates continuous monitoring into the following structured clinical and laboratory components:

  • Daily Clinical Monitorin
    1. General Appearance & Condition
    2. Behavior & Stress Indicators
    3. Grooming & Coat Condition
    4. Respiratory Patterns & Function
    5. Toxicity & Distress Signs
    6. Body Weight & Growth Monitoring
    7. Food Intake & Nutritional Status
    8. Hydration & Fluid Balance
  • Hematological & Biochemical
    1. Complete Blood Count (CBC)
    2. Clinical Biochemistry Panels
    3. Electrolyte & Mineral Balance
Send a Message

Request a Call Back

    1

    General Appearance & Condition

    General appearance is the first and most sensitive indicator of overall health status in animal studies. Subtle changes in posture, alertness, coat quality, or body symmetry often precede measurable laboratory abnormalities. Continuous visual assessment enables early identification of disease progression, discomfort, or treatment-related adverse effects. This parameter plays a critical role in welfare monitoring and study integrity. Accurate documentation strengthens both scientific validity and regulatory compliance.

    Applicable to regulatory evaluation of products with systemic safety considerations, including:

    1. Oral solid dosage forms (Tablet / Capsule)
    2. Injectable small-molecule drugs
    3. Biologics & Biosimilars with systemic exposure
    4. Combination products with systemic components
    read more

    General appearance is the first and most sensitive indicator of overall health status in animal studies. Subtle changes in posture, alertness, coat quality, or body symmetry often precede measurable laboratory abnormalities. Continuous visual assessment enables early identification of disease progression, discomfort, or treatment-related adverse effects. This parameter plays a critical role in welfare monitoring and study integrity. Accurate documentation strengthens both scientific validity and regulatory compliance.

    Applicable to regulatory evaluation of products with systemic safety considerations, including:

    1. Oral solid dosage forms (Tablet / Capsule)
    2. Injectable small-molecule drugs
    3. Biologics & Biosimilars with systemic exposure
    4. Combination products with systemic components
    Learn more

    2

    Behavior & Stress Indicators

    Behavioral and stress-related parameters provide real-time insight into neurological and physiological well-being. Alterations in activity levels, reactivity, social interaction, or anxiety-related behaviors may signal early toxicity or disease impact. Systematic behavioral monitoring allows differentiation between treatment effects and stress-induced artifacts. These readouts are essential for neuroscience, pharmacology, and safety studies. Behavioral stability is a cornerstone of reliable preclinical data.

    Relevant for regulatory assessment of products impacting the nervous system or stress-related pathways, including:

    1. CNS-active drugs (anxiolytics, antidepressants, neuroactive compounds)
    2. Biologics with neuro-immune interaction
    3. Long-term injectable therapies with central side effects
    4. Functional products claiming mood, cognition, or stress modulation
    read more

    Behavioral and stress-related parameters provide real-time insight into neurological and physiological well-being. Alterations in activity levels, reactivity, social interaction, or anxiety-related behaviors may signal early toxicity or disease impact. Systematic behavioral monitoring allows differentiation between treatment effects and stress-induced artifacts. These readouts are essential for neuroscience, pharmacology, and safety studies. Behavioral stability is a cornerstone of reliable preclinical data.

    Relevant for regulatory assessment of products impacting the nervous system or stress-related pathways, including:

    1. CNS-active drugs (anxiolytics, antidepressants, neuroactive compounds)
    2. Biologics with neuro-immune interaction
    3. Long-term injectable therapies with central side effects
    4. Functional products claiming mood, cognition, or stress modulation
    Learn more

    3

    Grooming & Coat Condition

    Grooming behavior and coat condition reflect both physical health and neurobehavioral status. Poor grooming, piloerection, or coat deterioration are often early signs of stress, pain, or systemic illness. Monitoring these features provides a non-invasive and highly sensitive welfare indicator. Changes in grooming patterns may also reveal neurotoxicity or metabolic imbalance. This parameter supports early intervention and ethical study conduct.

     Applicable to products affecting neurobehavioral, metabolic, or dermatological pathways, including:

    1. Chronic oral formulations with systemic exposure
    2. Metabolic and endocrine-active drugs
    3. Biologics affecting immune or inflammatory status
    4. Nutritional and functional products targeting skin or metabolism
    read more

    Grooming behavior and coat condition reflect both physical health and neurobehavioral status. Poor grooming, piloerection, or coat deterioration are often early signs of stress, pain, or systemic illness. Monitoring these features provides a non-invasive and highly sensitive welfare indicator. Changes in grooming patterns may also reveal neurotoxicity or metabolic imbalance. This parameter supports early intervention and ethical study conduct.

     Applicable to products affecting neurobehavioral, metabolic, or dermatological pathways, including:

    1. Chronic oral formulations with systemic exposure
    2. Metabolic and endocrine-active drugs
    3. Biologics affecting immune or inflammatory status
    4. Nutritional and functional products targeting skin or metabolism
    Learn more

    4

    Respiratory Patterns & Function

    Respiratory rate, rhythm, and effort are critical indicators of cardiopulmonary and systemic health. Abnormal breathing patterns may indicate drug toxicity, metabolic acidosis, infection, or neurological impairment. Continuous respiratory observation allows rapid detection of life-threatening conditions. This assessment is essential in toxicology, respiratory disease models, and safety pharmacology. Early identification protects animal welfare and data integrity.

     Critical for regulatory assessment of products with cardiopulmonary or metabolic risk, including:

    1. Injectable drugs with rapid systemic distribution
    2. Biologics with cytokine or immune activation potential
    3. Inhalation-adjacent or respiratory-risk compounds
    4. High-dose or first-in-class systemic therapies
    read more

    Respiratory rate, rhythm, and effort are critical indicators of cardiopulmonary and systemic health. Abnormal breathing patterns may indicate drug toxicity, metabolic acidosis, infection, or neurological impairment. Continuous respiratory observation allows rapid detection of life-threatening conditions. This assessment is essential in toxicology, respiratory disease models, and safety pharmacology. Early identification protects animal welfare and data integrity.

     Critical for regulatory assessment of products with cardiopulmonary or metabolic risk, including:

    1. Injectable drugs with rapid systemic distribution
    2. Biologics with cytokine or immune activation potential
    3. Inhalation-adjacent or respiratory-risk compounds
    4. High-dose or first-in-class systemic therapies
    Learn more

    5

    Toxicity & Distress Signs

    Systematic monitoring of toxicity and distress signs enables early recognition of adverse effects before irreversible damage occurs. Indicators such as lethargy, abnormal posture, vocalization, or pain-related behaviors are key safety signals. Early detection allows timely intervention, dose adjustment, or study termination when necessary. This monitoring is central to ethical responsibility and regulatory expectations. It forms the backbone of preclinical safety surveillance.

    Mandatory for regulatory safety evaluation of all preclinical development candidates, including:

    1. First-in-human candidate drugs
    2. Dose-escalation toxicology studies
    3. Biologics with unknown safety margins
    4. Combination products requiring integrated safety assessment
    read more

    Systematic monitoring of toxicity and distress signs enables early recognition of adverse effects before irreversible damage occurs. Indicators such as lethargy, abnormal posture, vocalization, or pain-related behaviors are key safety signals. Early detection allows timely intervention, dose adjustment, or study termination when necessary. This monitoring is central to ethical responsibility and regulatory expectations. It forms the backbone of preclinical safety surveillance.

    Mandatory for regulatory safety evaluation of all preclinical development candidates, including:

    1. First-in-human candidate drugs
    2. Dose-escalation toxicology studies
    3. Biologics with unknown safety margins
    4. Combination products requiring integrated safety assessment
    Learn more

    6

    Body Weight & Growth Monitoring

    Body weight and growth trends provide quantitative insight into metabolic status, treatment tolerance, and disease burden. Unintended weight loss or abnormal growth patterns often reflect toxicity, malnutrition, or systemic dysfunction. Regular measurement allows objective comparison across study groups and timepoints. This parameter is indispensable for toxicology, chronic disease, and developmental studies. Weight stability is a core marker of study viability.

    Applicable to products involving metabolic burden, chronic exposure, or developmental risk, including:

    1. Repeated-dose oral formulations
    2. Pediatric or developmental-stage relevant products
    3. Metabolic and endocrine therapies
    4. Long-term biologic treatments
    read more

    Body weight and growth trends provide quantitative insight into metabolic status, treatment tolerance, and disease burden. Unintended weight loss or abnormal growth patterns often reflect toxicity, malnutrition, or systemic dysfunction. Regular measurement allows objective comparison across study groups and timepoints. This parameter is indispensable for toxicology, chronic disease, and developmental studies. Weight stability is a core marker of study viability.

    Applicable to products involving metabolic burden, chronic exposure, or developmental risk, including:

    1. Repeated-dose oral formulations
    2. Pediatric or developmental-stage relevant products
    3. Metabolic and endocrine therapies
    4. Long-term biologic treatments
    Learn more

    7

    Food Intake & Nutritional Status

    Food intake monitoring reveals changes in appetite, metabolism, and overall physiological balance. Reduced or excessive consumption may indicate drug effects, stress response, or gastrointestinal dysfunction. Nutritional status directly influences immune function, growth, and behavioral outcomes. Accurate intake data improves interpretation of metabolic and pharmacological results. This assessment strengthens translational relevance of preclinical findings.

    Relevant for regulatory evaluation of products affecting metabolism, appetite, or gastrointestinal function, including:

    1. Metabolic and anti-obesity drugs
    2. GI-active oral formulations
    3. Functional foods and nutraceuticals
    4. Chronic therapies with appetite or absorption effects
    read more

    Food intake monitoring reveals changes in appetite, metabolism, and overall physiological balance. Reduced or excessive consumption may indicate drug effects, stress response, or gastrointestinal dysfunction. Nutritional status directly influences immune function, growth, and behavioral outcomes. Accurate intake data improves interpretation of metabolic and pharmacological results. This assessment strengthens translational relevance of preclinical findings.

    Relevant for regulatory evaluation of products affecting metabolism, appetite, or gastrointestinal function, including:

    1. Metabolic and anti-obesity drugs
    2. GI-active oral formulations
    3. Functional foods and nutraceuticals
    4. Chronic therapies with appetite or absorption effects
    Learn more

    8

    Hydration & Fluid Balance

    Hydration status is a critical determinant of cardiovascular stability, renal function, and metabolic homeostasis. Dehydration or fluid imbalance can rapidly confound study outcomes and compromise animal welfare. Monitoring water intake, skin turgor, and clinical signs ensures early detection of imbalance. This parameter is especially important in renal, metabolic, and toxicology studies. Proper hydration control safeguards both ethics and data quality.

     Essential for products with renal, cardiovascular, or fluid balance implications, including:

    • Renal and cardiovascular drugs
    • Injectable therapies influencing fluid homeostasis
    • Metabolic and electrolyte-modulating compounds
    • Toxicology studies with dehydration or renal risk
    read more

    Hydration status is a critical determinant of cardiovascular stability, renal function, and metabolic homeostasis. Dehydration or fluid imbalance can rapidly confound study outcomes and compromise animal welfare. Monitoring water intake, skin turgor, and clinical signs ensures early detection of imbalance. This parameter is especially important in renal, metabolic, and toxicology studies. Proper hydration control safeguards both ethics and data quality.

     Essential for products with renal, cardiovascular, or fluid balance implications, including:

    • Renal and cardiovascular drugs
    • Injectable therapies influencing fluid homeostasis
    • Metabolic and electrolyte-modulating compounds
    • Toxicology studies with dehydration or renal risk
    Learn more

    9

    Hematological Profiling (CBC & Differential)

    Hematological profiling through Complete Blood Count (CBC) and differential analysis provides a detailed window into systemic health, hematopoietic function, and immune status. This evaluation quantifies red blood cells (oxygen transport), white blood cells (immune response), platelets (clotting function), and hemoglobin levels. Differential leukocyte counts further characterize immune activation by identifying specific cell type proportions. Hematological data serve as sensitive indicators of toxicity, infection, inflammation, or bone marrow suppression, making them indispensable for comprehensive safety assessment in preclinical drug development and disease modeling.Comprehensive evaluation of blood cellular components  

    1. Complete Blood Count (CBC)
    2. Red Blood Cells (RBC)
    3. White Blood Cells (WBC)
    4. Hemoglobin (Hb)
    5. Hematocrit (Hct)
    6. Platelet Count (PLT)
    7. Differential Leukocyte Count
    read more

    Hematological profiling through Complete Blood Count (CBC) and differential analysis provides a detailed window into systemic health, hematopoietic function, and immune status. This evaluation quantifies red blood cells (oxygen transport), white blood cells (immune response), platelets (clotting function), and hemoglobin levels. Differential leukocyte counts further characterize immune activation by identifying specific cell type proportions. Hematological data serve as sensitive indicators of toxicity, infection, inflammation, or bone marrow suppression, making them indispensable for comprehensive safety assessment in preclinical drug development and disease modeling.Comprehensive evaluation of blood cellular components  

    1. Complete Blood Count (CBC)
    2. Red Blood Cells (RBC)
    3. White Blood Cells (WBC)
    4. Hemoglobin (Hb)
    5. Hematocrit (Hct)
    6. Platelet Count (PLT)
    7. Differential Leukocyte Count
    Learn more

    10

    Clinical Biochemistry Panels

    Clinical biochemistry panels deliver vital insights into organ function and metabolic status through quantitative serum/plasma biomarker analysis. Liver function markers (ALT, AST, ALP) detect hepatotoxicity, while renal markers (BUN, Creatinine) assess kidney health. Metabolic indicators like fasting glucose evaluate glycemic control, and lipid profiles (TG, LDL, HDL) monitor cardiovascular risk factors. These panels provide objective, quantitative measures of systemic toxicity and physiological response to therapeutic interventions, forming an essential component of safety pharmacology and toxicology studies required for regulatory approval. Organ function and metabolic status assessment through serum and plasma biomarkers.

    Liver Function Markers

    • ALT · AST · ALP

    Renal Function Markers

    • Blood Urea Nitrogen (BUN)
    • Creatinine

    Metabolic & Glycemic Indicators

    • Fasting Glucose

    Lipid Profile

    • Triglycerides (TG)
    • Low-Density Lipoprotein (LDL)
    • High-Density Lipoprotein (HDL)
    read more

    Clinical biochemistry panels deliver vital insights into organ function and metabolic status through quantitative serum/plasma biomarker analysis. Liver function markers (ALT, AST, ALP) detect hepatotoxicity, while renal markers (BUN, Creatinine) assess kidney health. Metabolic indicators like fasting glucose evaluate glycemic control, and lipid profiles (TG, LDL, HDL) monitor cardiovascular risk factors. These panels provide objective, quantitative measures of systemic toxicity and physiological response to therapeutic interventions, forming an essential component of safety pharmacology and toxicology studies required for regulatory approval. Organ function and metabolic status assessment through serum and plasma biomarkers.

    Liver Function Markers

    • ALT · AST · ALP

    Renal Function Markers

    • Blood Urea Nitrogen (BUN)
    • Creatinine

    Metabolic & Glycemic Indicators

    • Fasting Glucose

    Lipid Profile

    • Triglycerides (TG)
    • Low-Density Lipoprotein (LDL)
    • High-Density Lipoprotein (HDL)
    Learn more

    11

    Electrolyte & Mineral Balance Assessment

    Electrolyte and mineral balance assessment evaluates fundamental physiological homeostasis crucial for cellular function and systemic stability. Precise measurement of sodium, potassium, chloride, calcium, and phosphorus levels detects imbalances that may indicate renal dysfunction, endocrine disorders, metabolic disturbances, or treatment-related toxicity. Maintaining electrolyte equilibrium is essential for neuromuscular function, fluid balance, and biochemical processes. This assessment provides critical data for understanding drug effects on physiological stability and is a key parameter in comprehensive preclinical safety evaluations. Evaluation of systemic homeostasis and physiological stability.

    • Sodium (Na)
    • Potassium (K)
    • Chloride (Cl)
    • Calcium (Ca)
    • Phosphorus (P)
    read more

    Electrolyte and mineral balance assessment evaluates fundamental physiological homeostasis crucial for cellular function and systemic stability. Precise measurement of sodium, potassium, chloride, calcium, and phosphorus levels detects imbalances that may indicate renal dysfunction, endocrine disorders, metabolic disturbances, or treatment-related toxicity. Maintaining electrolyte equilibrium is essential for neuromuscular function, fluid balance, and biochemical processes. This assessment provides critical data for understanding drug effects on physiological stability and is a key parameter in comprehensive preclinical safety evaluations. Evaluation of systemic homeostasis and physiological stability.

    • Sodium (Na)
    • Potassium (K)
    • Chloride (Cl)
    • Calcium (Ca)
    • Phosphorus (P)
    Learn more
    This website uses cookies to improve your web experience.